Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Reata Pharmaceuticals, Inc. (RETA : NSDQ)
 
 • Company Description   
Reata Pharmaceuticals is a clinical-stage pharmaceutical company primarily focused on discovering, developing and commercializing small-molecule based innovative therapies for treating severe, life-threatening diseases with a few or no approved therapies. The company is developing its lead pipeline candidates - bardoxolone methyl (bardoxolone) and omaveloxolone for rare forms of chronic kidney disease (CKD) and neurological diseases, respectively.

Number of Employees: 349

 
 • Price / Volume Information   
Yesterday's Closing Price: $27.68 Daily Weekly Monthly
20 Day Moving Average: 513,449 shares
Shares Outstanding: 36.40 (millions)
Market Capitalization: $1,007.66 (millions)
Beta: 1.25
52 Week High: $153.41
52 Week Low: $20.24
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.88% 6.01%
12 Week 8.21% 18.97%
Year To Date 4.97% 28.25%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
5320 LEGACY DRIVE
-
PLANO,TX 75024
USA
ph: 972-865-2219
fax: -
ir@reatapharma.com http://www.reatapharma.com
 
 • General Corporate Information   
Officers
J. Warren Huff - Chief Executive Officer and Chairman of the Board
Manmeet S. Soni - Chief Operating Officer and Chief Financial Office
Bhaskar Anand - Vice President and Chief Accounting Officer
Martin W. Edward - Directors
William D. McClellan - Directors

Peer Information
Reata Pharmaceuticals, Inc. (CORR.)
Reata Pharmaceuticals, Inc. (RSPI)
Reata Pharmaceuticals, Inc. (CGXP)
Reata Pharmaceuticals, Inc. (BGEN)
Reata Pharmaceuticals, Inc. (GTBP)
Reata Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 75615P103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 36.40
Most Recent Split Date: (:1)
Beta: 1.25
Market Capitalization: $1,007.66 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.90 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-8.34 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 7.89
Price/Cash Flow: -
Price / Sales: 87.93
EPS Growth
vs. Year Ago Period: -9.14%
vs. Previous Quarter: 13.62%
Sales Growth
vs. Year Ago Period: -3.18%
vs. Previous Quarter: -2.14%
ROE
03/31/22 - -137.52
12/31/21 - -105.72
09/30/21 - -81.91
ROA
03/31/22 - -41.55
12/31/21 - -38.88
09/30/21 - -34.92
Current Ratio
03/31/22 - 12.32
12/31/21 - 11.05
09/30/21 - 5.95
Quick Ratio
03/31/22 - 12.32
12/31/21 - 11.05
09/30/21 - 5.95
Operating Margin
03/31/22 - -2,650.72
12/31/21 - -2,588.22
09/30/21 - -2,020.49
Net Margin
03/31/22 - -2,650.72
12/31/21 - -2,588.22
09/30/21 - -2,020.49
Pre-Tax Margin
03/31/22 - -2,654.25
12/31/21 - -2,592.13
09/30/21 - -2,026.45
Book Value
03/31/22 - 3.51
12/31/21 - 5.11
09/30/21 - 7.03
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©